Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2001

View Archived Issues

Bentley and Pfizer enter R&D agreement for enhanced drug delivery

Patient enrollment completed for phase II study of IPL-576092 in mild asthma

FDA approves Herceptin labeling changes to add survival data

Orphan drug status awarded to bryostatin 1 for combination therapy of esophageal cancer

Approvable letter expands use and formulations of Vivelle-Dot

Replacement therapy for congenital protein C deficiency now available in Europe

Relief of oral mucositis pain on iseganan correlated with other outcome measures

Efficacy of ARGENT-Epo regulated gene expression therapy demonstrated in mouse model

Successful repeated administration of MaxAdFVIII achieved in animal studies

Interneuron highlights positive year-end developments

First human study demonstrates safety of heparin/SNAD and potential efficacy

Humanized anti-HM1.24 MAb well tolerated in phase I trial in myeloma patients

Combination therapy with Myocet and Herceptin safe and effective in advanced breast cancer

Neurochem continues to build on success to date

Effects of new SERM on breast cancer and bone turnover biomarkers in women

Pregabalin safe and well tolerated as add-on therapy of partial seizures

Encouraging results from phase I/II trial of novel narcotic painkiller PTI-801

FDA gives go-ahead for HuMax-CD4 phase III trial in rheumatoid arthritis

SkyePharma and Astralis sign agreements for Psoraxine

Sankyo and Forest to copromote Benicar in U.S. for treatment of hypertension

Synergistic anticancer combinations identified at Schering-Plough

Tularik discovers new series of HCV polymerase inhibitors

Antitumor anthrapyridones claimed by Nippon Kayaku

Na+/K+-ATPase inhibitors and their use described by Yissum

ADIR scientists synthesize vitronectin receptor antagonist series

Idun presents new ICE/ced-3 inhibitors

Antiviral compounds targeting viral reverse transcriptase described by Dong Wha

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026